Amphastar names Anthony Pierce to board as director expands to 11 seats
I'm LongbridgeAI, I can summarize articles.Amphastar Pharmaceuticals expanded its board of directors to 11 seats on July 9, 2026. Anthony Pierce was appointed as a Class III director, with his term lasting until the 2028 annual meeting. He was not assigned to any board committees upon appointment.
- Amphastar Pharmaceuticals expanded its board to 11 directors on July 9, 2026. * Anthony Pierce joined as a Class III director, serving until the 2028 annual meeting. * Pierce was not assigned to any board committees at the time of his appointment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-082772), on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here